Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

  • Assays
  • 1

Filter Results (13)

  • Research Grant, 2018
    Studying Changes in Glucocerebrosidase Activity in People with Parkinson's Disease

    Study Rationale:
    A dysfunction of the glucocerebrosidase (GCase) protein increases the risk of Parkinson's disease (PD). Blood cells called monocytes produce large amounts of this protein. The aim of...

  • Research Grant, 2018
    Improving Existing LRRK2 Tests with Novel Reagents

    Promising Outcomes of Original Grant:
    The goal of our original study was to determine the best conditions for collecting and processing blood cells intended for testing the function of LRRK2, a protein...

  • Research Grant, 2018
    Development of Experimental Setups Using New Antibodies to Detect Alpha-synuclein in Cerebrospinal Fluid

    Study Rationale:
    Research studies have yet to clearly explain whether alpha-synuclein oligomers -- clumps of protein alpha-synuclein -- in biologicals fluids can be used in clinics as measures of...

  • Research Grant, 2018
    Evaluation and Comparison of Existing Tests for Alpha-synuclein

    Study Rationale:
    An increase in the levels of alpha-synuclein -- a sticky protein that clumps in the brains of people with Parkinson's disease (PD) -- has been directly linked to an increased risk of...

  • Access to Data and Biospecimens, 2018
    A New Test for Rapid and Ultra-Sensitive Detection of Hallmarks of Parkinson's Disease in Cerebrospinal Fluid

    Study Rationale:
    The diagnosis and treatment of Parkinson's disease (PD) would be aided by the availability of direct and highly sensitive tests for the abnormal clumps of protein alpha-synuclein...

  • Oligomeric & pS129 Assay LEAPS, 2017
    Exploring the Use of Alpha-synuclein Assays for Translational Biomarkers and Pharmaceutical Intervention Trials

    Study Rationale:
    Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. The biggest roadblock facing the development of disease-modifying therapies is...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.